Sleep Apnea, Obstructive Completed Phase 3 Trials for Armodafinil (DB06413)

Also known as: Obstructive Sleep Apnea (OSAS) / Apnea, Obstructive Sleep / Obstructive Sleep Apnea / Obstructive Sleep Apnea (OSA) / Obstrutive Sleep Apnea / Sleep Obstructive Apnea / Sleep Apnea - Obstructive / Sleep Apnea, Obstructives / Sleep Apnea Obstructive (OSA) / OSA - Obstructive Sleep Apnea / Obstructive Sleep Apnea (SAOS) / Sleep Apnea Syndrome (OSAS) / OSA / OSAS / OSAS (Obstructive Sleep Apneas Syndrome) / Obstructive Sleep Apnea Syndromes / Obstructive Sleep Apnea Syndrome and / Sleep Apnea Syndromes, Obstructive / Obstructive Sleep-Apnea Syndrome / Obstructive Sleep Apnoea Syndrome / Syndrome, Obstructive Sleep Apnea / Obstructive Sleep Apnea Syndrome (OSAS) / Obstructive Sleep Apnea Syndrome / Obstructive sleep apnea hypopnea / Sleep apnea syndrome / Sleep Apnea Syndromes / Sleep apnoea syndromes / Sleep apnea / Sleep apnoea syndrome / Apnea syndrome / Apnoea syndrome / Sleep apnoeas / Sleep apnoea

IndicationStatusPhase
DBCOND0030275 (Sleep Apnea, Obstructive)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00078312Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep DisorderTreatment
NCT02478580Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese PatientsPrevention
NCT00078325Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)Treatment
NCT00079677Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) SyndromeTreatment